Yahoo
NasdaqGS - Delayed Quote USD

Alumis Inc. (ALMS)

11.36 +1.01 (+9.76%)
At close: September 3 at 4:00:01 PM EDT
11.45 +0.09 (+0.79%)
Pre-Market: 8:22:47 AM EDT
Trade Alumis on Coinbase
Chart Range Bar
Loading chart for ALMS
  • Previous Close 10.35
  • Open 10.35
  • Bid 9.47 x 100
  • Ask 10.23 x 100
  • Day's Range 10.31 - 11.92
  • 52 Week Range 3.76 - 31.35
  • Volume 7,547,463
  • Avg. Volume 1,970,895
  • Market Cap (intraday) 1.47B
  • Beta (5Y Monthly) -0.79
  • PE Ratio (TTM) --
  • EPS (TTM) -4.52
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 32.33

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

www.alumis.com

237

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ALMS
16.39%
S&P 500 (^GSPC)
13.18%

1-Year Return

ALMS
142.74%
S&P 500 (^GSPC)
20.15%

3-Year Return

ALMS
15.85%
S&P 500 (^GSPC)
71.57%

5-Year Return

ALMS
15.85%
S&P 500 (^GSPC)
70.83%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 1.74M
Earnings -93.05M
Profit Margin -5,344.80%

Q3

FY25

Q4

FY25

Q1

FY26

-100M
-80M
-60M
-40M
-20M
0
-5300.0%
-5200.0%
-5100.0%
-5000.0%
-4900.0%

Analyst Insights

View More

Analyst Price Targets

15.00
32.33 Average
11.36 Current
46.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/3/2026
Analyst Guggenheim
Rating Action Downgrade
Rating Neutral
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    1.26B

  • Enterprise Value

    798.33M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    147.85

  • Price/Book (mrq)

    2.71

  • Enterprise Value/Revenue

    107.91

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -45.34%

  • Return on Equity (ttm)

    -93.65%

  • Revenue (ttm)

    7.4M

  • Net Income Avi to Common (ttm)

    -438.96M

  • Diluted EPS (ttm)

    -4.52

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    502.29M

  • Total Debt/Equity (mrq)

    8.06%

  • Levered Free Cash Flow (ttm)

    -208.64M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

11.36 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: